Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases ...
Congrats on adding HRTS to your portfolio! It's interesting to see a fund focused on companies involved in cardiovascular and metabolic disease treatments. With the growing importance of healthcare and biotech, this could be a promising investment.
Have you done any research on the fund's holdings or top positions? Are there any specific companies or areas within the cardiovascular and metabolic disease spaces that you're excited about?
Congrats on adding HRTS to your portfolio! It's interesting to see a fund focused on companies involved in cardiovascular and metabolic disease treatments. With the growing importance of healthcare and biotech, this could be a promising investment.
Have you done any research on the fund's holdings or top positions? Are there any specific companies or areas within the cardiovascular and metabolic disease spaces that you're excited about?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
